2020
Stage III uterine serous carcinoma: modern trends in multimodality treatment
Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaExternal beam RTVaginal brachytherapyOverall survivalHuman epidermal growth factor receptorModern treatment eraSentinel node samplingRegional nodal recurrenceKaplan-Meier estimatesLog-rank testCox proportional hazardsExternal beam radiotherapyEpidermal growth factor receptorERA treatmentGrowth factor receptorUSC patientsFree survivalNodal recurrenceTreatment eraMultimodality treatmentPatient characteristicsPerioperative periodRegional nodalSerous carcinomaNode sampling
2017
Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer
Qian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: 0. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBody Mass IndexBrachytherapyConstriction, PathologicDatabases, FactualEndometrial NeoplasmsFemaleGastrointestinal DiseasesGravidityHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm StagingOvariectomyRadiation InjuriesRadiotherapy, AdjuvantSalpingectomyTreatment OutcomeVaginaVaginal DiseasesConceptsVaginal brachytherapyVaginal symptomsLate grade 3 toxicityEarly-stage endometrial cancerNormal body mass indexAdjuvant vaginal brachytherapyGrade 3 toxicityShorter vaginal lengthStage endometrial cancerEndometrial cancer patientsBody mass indexRate of recurrenceAcute gastrointestinalTreatment tolerabilityVaginal stenosisEndometrial cancerVaginal lengthMass indexRecurrence rateCancer patientsVaginal toxicityTreatment characteristicsHigh riskSide effectsPatients
2014
Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer
Damast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative Patient-Centered Outcomes (Health State and Adverse Sexual Symptoms) Between Adjuvant Brachytherapy Versus No Adjuvant Brachytherapy in Early Stage Endometrial Cancer. Annals Of Surgical Oncology 2014, 21: 2740-2754. PMID: 24619493, DOI: 10.1245/s10434-014-3562-4.Peer-Reviewed Original ResearchConceptsFemale Sexual Function IndexPoor health statesSexual functioningEndometrial cancerSexual functionEarly-stage endometrial cancerHealth statesStage I endometrial cancerBaseline sexual activityStage endometrial cancerEndometrial cancer survivorsSexual Function IndexSignificant risk factorsSurgery groupUnderwent surgeryEQ5D scoresFSFI scoreSurgery typeAdjuvant brachytherapyCancer survivorsMore frequent useRisk factorsFunction IndexSexual dysfunctionMultivariable regression
2012
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer
Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer. Gynecologic Oncology 2012, 127: 321-325. PMID: 22850412, DOI: 10.1016/j.ygyno.2012.07.112.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBrachytherapyCarboplatinChemoradiotherapy, AdjuvantCystadenocarcinoma, PapillaryCystadenocarcinoma, SerousDrug Administration ScheduleEndometrial NeoplasmsFemaleFollow-Up StudiesHumansHysterectomyMiddle AgedNeoplasm StagingOvariectomyPaclitaxelRetrospective StudiesSalpingectomySurvival AnalysisTreatment OutcomeConceptsCarboplatin/paclitaxel chemotherapyUterine papillary serous carcinomaPaclitaxel chemotherapyStage IEarly-stage uterine papillary serous carcinomaPapillary serous endometrial cancerParaaortic lymph node samplingDistant recurrence ratesMedian patient ageStage II diseaseFive-year outcomesLymph node samplingKaplan-Meier methodOverall survival ratePapillary serous carcinomaSingle institution experienceLog-rank testSerous endometrial cancerConcurrent carboplatinMedian followPelvic radiationOmental biopsyPara-aorticPelvic recurrenceUnderwent surgerySexual Functioning Among Endometrial Cancer Patients Treated With Adjuvant High-Dose-Rate Intra-Vaginal Radiation Therapy
Damast S, Alektiar KM, Goldfarb S, Eaton A, Patil S, Mosenkis J, Bennett A, Atkinson T, Jewell E, Leitao M, Barakat R, Carter J, Basch E. Sexual Functioning Among Endometrial Cancer Patients Treated With Adjuvant High-Dose-Rate Intra-Vaginal Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: e187-e193. PMID: 22572074, PMCID: PMC5538259, DOI: 10.1016/j.ijrobp.2012.03.030.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravaginalAdolescentAdultAgedAged, 80 and overBrachytherapyCross-Sectional StudiesDehydrationDilatationEndometrial NeoplasmsFemaleHumansHysterectomyLaparotomyLibidoMiddle AgedOrgasmPainPersonal SatisfactionRadiotherapy DosageRadiotherapy, AdjuvantReference ValuesRegression AnalysisRisk FactorsSexual Dysfunction, PhysiologicalSurveys and QuestionnairesVaginal Creams, Foams, and JelliesVaginal DiseasesYoung AdultConceptsFemale Sexual Function IndexEndometrial cancer patientsSexual dysfunctionFSFI scoreSexual functioningCancer patientsEarly stage endometrial cancer patientsQuestionnaire completionRates of SDLubricant useLower FSFI scoresSexual Function IndexPoor sexual functioningRadiation oncology clinicPostmenopausal statusSimple hysterectomyPostmenopausal populationOncology clinicAdjuvant brachytherapyEC patientsRisk factorsFunction IndexRadiation therapyHigh doseMultivariate analysis
2010
Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases
Damast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of Dose on Local Failure Rates After Image-Guided Reirradiation of Recurrent Paraspinal Metastases. International Journal Of Radiation Oncology • Biology • Physics 2010, 81: 819-826. PMID: 20888133, DOI: 10.1016/j.ijrobp.2010.06.013.Peer-Reviewed Original ResearchConceptsImage-guided intensity-modulated radiotherapyLocal failure rateParaspinal metastasisImpact of doseDaily fractionsIncidence of myelopathySingle-fraction regimensRecords of patientsRisk of myelopathyIntensity-modulated radiotherapyCumulative incidenceEpidural diseaseField recurrenceDose groupProspective dataFailure rateTreatment characteristicsLF incidenceMetastasisIncidenceSignificant decreaseGyMyelopathyDoseIg
2009
Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era
Damast S, Ho AY, Montgomery L, Fornier MN, Ishill N, Elkin E, Beal K, McCormick B. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era. International Journal Of Radiation Oncology • Biology • Physics 2009, 77: 1105-1112. PMID: 19879068, DOI: 10.1016/j.ijrobp.2009.06.042.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabineCarboplatinCyclophosphamideDeoxycytidineDisease-Free SurvivalDose Fractionation, RadiationDoxorubicinDrug Administration ScheduleEpirubicinFemaleFluorouracilHumansMastectomy, Modified RadicalMiddle AgedNeoadjuvant TherapyPaclitaxelRadiodermatitisRadiotherapy, AdjuvantRetrospective StudiesConceptsDistant metastasis-free survivalStandard fractionation radiationCombined-modality therapyInflammatory breast cancer patientsMetastasis-free survivalBreast cancer patientsLocoregional controlRadiation therapyLocoregional outcomeSkin bolusCancer patientsChest wallAdjuvant radiation therapyExcellent locoregional controlMajority of patientsSignificant therapeutic challengeScar boostTaxane eraIBC patientsRadical mastectomyRegional lymphaticsTherapeutic challengeDaily fractionsStandard fractionationPrescribed treatment